This clinical presentation on Rheuma TV examines the therapeutic role of Sulfasalazine as a disease-modifying antirheumatic drug (DMARD) in rheumatology. The session covers clinical indications for autoimmune conditions—such as rheumatoid arthritis, peripheral spondyloarthritis, and psoriatic arthritis—alongside safety concerns, dosing protocols, monitoring strategies, and proactive management of potential adverse events (e.g., GI intolerance, mucocutaneous reactions, hepatotoxicity, and hematological toxicity like agranulocytosis).
